EBS - Emergent BioSolutions CEO asked to testify on federal vaccine contracts

Launching an investigation into the vaccine contracts secured by Emergent BioSolutions ([[EBS]] -3.8%), the House Oversight Committee and the Select Subcommittee on the coronavirus crisis have asked the CEO and executive chairman of the company asking them to testify at a hearing on May 19.According to a statement from panel chairs Carolyn Maloney and Jim Clyburn, the House is launching the investigation to probe if the company used its connections with a former administration official to profit from the vaccine contracts.“Specifically, we are investigating reports that Emergent received multi-million-dollar contracts to manufacture coronavirus vaccines despite a long, documented history of inadequately trained staff and quality control issues,” the Chairs noted.Recently, Emergent BioSolutions has come under pressure after 15M doses of JNJ’s COVID-19 vaccine doses manufactured at its Bayview facility got contaminated due to a human error. The FDA inspections on the site were ongoing, the company announced yesterday.

For further details see:

Emergent BioSolutions CEO asked to testify on federal vaccine contracts